# Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

> **NCT01454063** · PHASE3 · COMPLETED · sponsor: **Omeros Corporation** · enrollment: 405 (actual)

## Conditions studied

- Intraocular Lens Replacement

## Interventions

- **DRUG:** OMS302
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01454063
- **Lead sponsor:** Omeros Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2014-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454063, "Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01454063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*